HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial resultsDavid A. Braun, David Sommerhalder, Ryan H. Moy et al.|Cell Reports Medicine|2026Cited by 1